Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 1.6% Higher – Here’s Why

by · The Cerbat Gem

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) shares rose 1.6% during mid-day trading on Wednesday . The company traded as high as $6.62 and last traded at $6.54. Approximately 1,044,577 shares traded hands during trading, a decline of 82% from the average daily volume of 5,804,447 shares. The stock had previously closed at $6.44.

Analysts Set New Price Targets

Several research analysts recently commented on RXRX shares. Needham & Company LLC reduced their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th. Jefferies Financial Group decreased their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. KeyCorp dropped their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Finally, Leerink Partners decreased their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of “Hold” and an average target price of $9.40.

Check Out Our Latest Stock Report on Recursion Pharmaceuticals

Recursion Pharmaceuticals Trading Up 7.1 %

The company has a market capitalization of $1.57 billion, a PE ratio of -4.11 and a beta of 0.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The company’s fifty day moving average is $6.70 and its 200-day moving average is $7.93.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The company had revenue of $14.42 million during the quarter, compared to the consensus estimate of $11.96 million. During the same period in the previous year, the firm posted ($0.38) earnings per share. The company’s revenue was up 30.9% on a year-over-year basis. On average, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Insider Activity

In related news, COO Tina Marriott sold 6,000 shares of the stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $8.13, for a total transaction of $48,780.00. Following the completion of the sale, the chief operating officer now owns 535,457 shares of the company’s stock, valued at $4,353,265.41. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $8.13, for a total transaction of $48,780.00. Following the transaction, the chief operating officer now directly owns 535,457 shares in the company, valued at $4,353,265.41. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Christopher Gibson sold 30,000 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.10, for a total value of $213,000.00. Following the completion of the sale, the chief executive officer now owns 758,738 shares of the company’s stock, valued at approximately $5,387,039.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 201,682 shares of company stock worth $1,353,652. Corporate insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of Recursion Pharmaceuticals during the first quarter valued at $26,000. GAMMA Investing LLC lifted its position in Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after acquiring an additional 6,036 shares during the period. Amalgamated Bank grew its stake in Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after purchasing an additional 2,459 shares during the last quarter. San Luis Wealth Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the third quarter valued at about $69,000. Finally, Midwest Financial Group LLC purchased a new position in shares of Recursion Pharmaceuticals in the second quarter worth about $90,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Featured Stories